Immix Biopharma Announces Patient Dosing in Ongoing Phase
Dec 13, 2022 · IMX-110 clinical trial data is expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110.
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b…
Dec 20, 2022 · 16 th patient dosed with IMX-110 to date; This is the second patient dosed with IMX-110 in December 2022; Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to …
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim …
Jan 19, 2022 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a life-threatening form of …
Immix Biopharma Announces Early Positive IMX-110 Interim …
May 3, 2023 · IMMINENT-01 is a first-of-its-kind, ongoing phase 1b/2a clinical trial combining tissue specific therapeutic IMX-110 with BeiGene / Novartis' anti-PD-1 antibody tislelizumab, in patients with advanced solid tumors.
Immix Observes Clinical Benefit at Dose-Level 2 in Phase 1b …
Dec 10, 2018 · IMX-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. IMX-110 contains NF-kB/Stat3/pan-tyrosine kinase inhibitor...
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients ...
LOS ANGELES, Feb. 4, 2020 /PRNewswire/ -- Immix Biopharma, Inc., announced today that the first patient in the USA was dosed successfully in its flagship phase 1b /2a clinical trial testing...
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim
Jan 19, 2022 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation...
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX …
Immix Biopharma, Inc, a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the fifteenth patient dosed with IMX-110 to-date.
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b…
Dec 20, 2022 · IMX-110 is currently being evaluated in a phase 1b/2a clinical trial in patients with advanced solid tumors. Learn more at www.immixbio.com/iMX-110
Immix Receives FDA Authorization to Expand Clinical Trial ... - BioSpace
Immix Biopharma, Inc announced that it received a letter from the FDA authorizing it to proceed with expanding its phase 1b/2a clinical trial of IMX-110 to the United States under an IND.